Additional Safety and Exploratory Efficacy Data at 48 and 60 Months from Open-HART, an Open-Label Extension Study of Pridopidine in Huntington Disease.
暂无分享,去创建一个
M. Hayden | K. Kieburtz | S. Papapetropoulos | P. Auinger | M. Geva | M. Gordon | I. Grachev | J. Savola | S. Gandhi | V. Abler | M. Mehra | A. McGarry